We used two different inhibitors against the VEGF pathway: bevacizumab, the monoclonal antibody that blocks the ligand VEGF secreted by the tumor cells, and sorafenib, a small-molecule TKI that targets VEGFR expressed by both endothelial cells (in the stroma) and cancer cells. Here, KDR is linked to cancer.